These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating Dopamine Agonistic Therapy in Psychiatry. Gold MS; Badgaiyan RD; Blum K Psychiatr Clin North Am; 2015 Sep; 38(3):419-62. PubMed ID: 26300032 [TBL] [Abstract][Full Text] [Related]
3. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2. Blum K; Chen TJ; Morse S; Giordano J; Chen AL; Thompson J; Allen C; Smolen A; Lubar J; Stice E; Downs BW; Waite RL; Madigan MA; Kerner M; Fornari F; Braverman ER Postgrad Med; 2010 Nov; 122(6):214-26. PubMed ID: 21084796 [TBL] [Abstract][Full Text] [Related]
5. Novel pharmacological approaches to drug abuse treatment. Edens E; Massa A; Petrakis I Curr Top Behav Neurosci; 2010; 3():343-86. PubMed ID: 21161760 [TBL] [Abstract][Full Text] [Related]
6. Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis. Blum K; Gold MS Med Hypotheses; 2011 Apr; 76(4):576-84. PubMed ID: 21306831 [TBL] [Abstract][Full Text] [Related]
7. [The neurobiology of psychostimulant addiction]. Fernández-Espejo E Rev Neurol; 2006 Aug 1-15; 43(3):147-54. PubMed ID: 16871480 [TBL] [Abstract][Full Text] [Related]
8. Neurobehavioral Sequelae of Psychostimulant Abuse. Djamshidian A Int Rev Neurobiol; 2015; 120():161-77. PubMed ID: 26070757 [TBL] [Abstract][Full Text] [Related]
9. Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis. Keck TM; John WS; Czoty PW; Nader MA; Newman AH J Med Chem; 2015 Jul; 58(14):5361-80. PubMed ID: 25826710 [TBL] [Abstract][Full Text] [Related]
11. [Assessment of addiction to psychotropic medications]. Bischof G; John U; Rumpf HJ Dtsch Med Wochenschr; 2009 Nov; 134(47):2397-8. PubMed ID: 19911329 [No Abstract] [Full Text] [Related]
12. Drug Therapy. He RH; Tao R Adv Exp Med Biol; 2017; 1010():219-245. PubMed ID: 29098675 [TBL] [Abstract][Full Text] [Related]
13. Rebalancing the Addicted Brain: Oxytocin Interference with the Neural Substrates of Addiction. Bowen MT; Neumann ID Trends Neurosci; 2017 Dec; 40(12):691-708. PubMed ID: 29128108 [TBL] [Abstract][Full Text] [Related]
14. Pro- and anti-addictive neurotrophic factors and cytokines in psychostimulant addiction: mini review. Yamada K; Nabeshima T Ann N Y Acad Sci; 2004 Oct; 1025():198-204. PubMed ID: 15542718 [TBL] [Abstract][Full Text] [Related]
15. Introduction to special issue "addiction pharmacotherapy and special populations". McCance-Katz EF Subst Use Misuse; 2005; 40(13-14):1895-7. PubMed ID: 16282084 [No Abstract] [Full Text] [Related]
16. Health for life. Addiction: how to break the chain. Miller MC Newsweek; 2005 Dec; 146(24):58. PubMed ID: 16375164 [No Abstract] [Full Text] [Related]
17. The role of impulsivity in psychostimulant- and stress-induced dopamine release: Review of human imaging studies. Bosker WM; Neuner I; Shah NJ Neurosci Biobehav Rev; 2017 Jul; 78():82-90. PubMed ID: 28438467 [TBL] [Abstract][Full Text] [Related]